Please wait a minute...
购物车 申请加入邮件组 English
高级检索 图表检索
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

邮发代号 80-967

2019 Impact Factor: 3.421

热点文章  |  下载排行  |  浏览排行
在线投稿 免费RSS订阅
Frontiers of Medicine  2020, Vol. 14 Issue (2): 210-214   https://doi.org/10.1007/s11684-020-0757-x
  本期目录
Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19
Li Ni1, Ling Zhou1, Min Zhou2, Jianping Zhao2, Dao Wen Wang1()
1. Division of Cardiology;
2. Division of Respiration, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
 全文: PDF(951 KB)   HTML
Abstract：

In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.
Key words： novel coronavirus (2019-nCoV)    COVID-19    Chinese traditional patent medicine    Shuanghuanglian oral liquid
收稿日期: 2020-02-16      出版日期: 2020-05-09
Corresponding Author(s): Dao Wen Wang   
 引用本文:   
. [J]. Frontiers of Medicine, 2020, 14(2): 210-214.
Li Ni, Ling Zhou, Min Zhou, Jianping Zhao, Dao Wen Wang. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front. Med., 2020, 14(2): 210-214.
 链接本文:  
https://academic.hep.com.cn/fmd/CN/10.1007/s11684-020-0757-x
https://academic.hep.com.cn/fmd/CN/Y2020/V14/I2/210
Fig.1  
Specimen Case 1 Case 2 Case 3
Illness day 12 Illness day 20 Illness day 23 Illness day 3 Illness day 11 Illness day 14 Illness day 3 Illness day 11
Nasopharyngeal swab Negative Negative NT Negative Negative NT Positive Negative
Anal swab NT NT Negative NT NT Negative NT NT
Tab.1  
Fig.2  
Measure Reference range Illness day 13 Illness day 24
Hospital day 2 Hospital day 13
White cell count (×109/L) 3.50–9.50 5.93 5.46
Red cell count (×109/L) 3.80–5.10 4.13 4.06
Neutrophil count (×109/L) 1.90–6.30 3.04 3.27
Lymphocyte count (×109/L) 1.10–3.20 2.11 1.5
Eosinophil count (×109/L) 0.02–0.52 0.12 0.15
Platelet count (×109/L) 125.0–350.0 361 323
Hemoglobin (g/L) 115.0–150.0 113 111
Hematocrit (%) 35.0–45.0 35 35
Sodium (mmol/L) 136–214 140 140.4
Potassium (mmol/L) 3.50–5.10 4.22 4.8
Chloride (mmol/L) 99–110 104.6 102.4
Calcium (mmol/L) 2.15–2.50 2.06 ↓ 2.19
Carbon dioxide (mmol/L) 22.0–29.0 21 ↓ 25.1
Glucose (mmol/L) 4.11–6.05 – 5.01
Blood urea nitrogen (mmol/L) 2.6–7.5 3.1 3.6
Creatinine (mmol/L) 45–84 53 60
Total protein (g/L) 64–83 68.4 68.6
Albumin (g/L) 35–52 29.6 ↓ 33.2 ↓
Total bilirubin (mmol/L) ≤21 6.4 4.5
Procalcitonin (ng/mL) ≤0.05 0.03 0.03
Alanine aminotransferase (U/L) ≤33 17 20
Aspartate aminotransferase (U/L) ≤32 16 19
Alkaline phosphatase (U/L) 35–105 59 83
Fibrinogen (g/L) 2.00–4.00 5.31 ↑ –
Lactate dehydrogenase (U/L) 135–214 248 ↑ –
Prothrombin time (s) 11.5–14.5 13.6 –
International normalized ratio 0.80–1.20 1.03 –
Creatine kinase (U/L) ≤170 35 27
C-reactive protein (mg/L) ≤3 57.8 ↑ –
Tab.2  
Fig.3  
Measure Reference range Illness day 4 Illness day 15
Hospital day 2 Hospital day 13
White cell count (×109/L) 3.50–9.50 3.63 5.79
Red cell count (×109/L) 3.80–5.10 4.5 4.28
Neutrophil count (×109/L) 1.90–6.30 2.12 3.2
Lymphocyte count (×109/L) 1.10–3.20 1.25 1.98
Eosinophil count (×109/L) 0.02–0.52 0.01 0.17
Platelet count (×109/L) 125.0–350.0 139 308
Hemoglobin (g/L) 115.0–150.0 125 117
Hematocrit (%) 35.0–45.0 37.9 36.2
Sodium (mmol/L) 136–214 135.3 143.5
Potassium (mmol/L) 3.50–5.10 3.69 4.27
Chloride (mmol/ L) 99–110 97 ↓ 106.3
Calcium (mmol/L) 2.15–2.50 2.25 2.27
Carbon dioxide (mmol/L) 22.0–29.0 22.3 25.2
Glucose (mmol/L) 4.11–6.05 4.31 4.82
Blood urea nitrogen (mmol/L) 2.6–7.5 2.7 3.4
Creatinine (mmol/L) 45–84 59 52
Total protein (g L) 64–83 77.2 65.6
Albumin (g/L) 35–52 41.5 37.5
Total bilirubin (mmol/L) ≤21 6.6 4
Procalcitonin (ng/mL) ≤0.05 0.04 –
Alanine aminotransferase (U/L) ≤33 8 50 ↑
Aspartate aminotransferase (U/L) ≤32 21 27
Alkaline phosphatase (U/L) 35–105 52 22 ↓
Fibrinogen (g/L) 2.00–4.00 3.42 –
Lactate dehydrogenase (U/L) 135–214 170 186
Prothrombin time (s) 11.5–14.5 13.6 –
International normalized ratio 0.80–1.20 1.03 –
Creatine kinase (U/L) ≤170 52 27
C-reactive protein (mg/L) ≤3 9.4 ↑ –
Tab.3  
Fig.4  
1 N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, P Niu, F Zhan, X Ma, D Wang, W Xu, G Wu, GF Gao, W; Tan China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733
https://doi.org/10.1056/NEJMoa2001017 pmid: 31978945
2 Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Liu, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JTK Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316
https://doi.org/10.1056/NEJMoa2001316 pmid: 31995857
3 National Health Commission of the People’s Republic of China. Latest update on Novel Coronavirus Pneumonia as of 24:00, February 14, 2020. 2020. (in Chinese) (accessed February 15, 2020)
4 ML Holshue, C DeBolt, S Lindquist, KH Lofy, J Wiesman, H Bruce, C Spitters, K Ericson, S Wilkerson, A Tural, G Diaz, A Cohn, L Fox, A Patel, SI Gerber, L Kim, S Tong, X Lu, S Lindstrom, MA Pallansch, WC Weldon, HM Biggs, TM Uyeki, SK; Pillai Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020 Jan 31. [Epub ahead of print] doi: 10.1056/NEJMoa2001191
https://doi.org/10.1056/NEJMoa2001191 pmid: 32004427
5 JF Chan, S Yuan, KH Kok, KK To, H Chu, J Yang, F Xing, J Liu, CC Yip, RW Poon, HW Tsoi, SK Lo, KH Chan, VK Poon, WM Chan, JD Ip, JP Cai, VC Cheng, H Chen, CK Hui, KY Yuen. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514–523
https://doi.org/10.1016/S0140-6736(20)30154-9 pmid: 31986261
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed